Financial Performance - Net profit attributable to shareholders decreased by 24.92% to CNY 26,863,537.79 compared to the same period last year[5] - Operating income rose by 2.33% to CNY 415,958,437.10, indicating stable business growth after excluding pandemic-related fluctuations[5] - Basic and diluted earnings per share decreased by 29.78% to CNY 0.0481[5] - The weighted average return on equity decreased by 1.01 percentage points to 1.81%[5] - The company reported a net profit increase, with retained earnings growing to CNY 211,117,015.25 from CNY 184,253,477.46, a rise of approximately 14.6%[23] - Net profit for Q1 2021 was ¥26,632,438.79, down 23.5% from ¥34,810,144.04 in Q1 2020[31] - The company reported a gross profit margin of approximately 9.1% in Q1 2021, compared to 10.0% in Q1 2020[30] Assets and Liabilities - Total assets increased by 10.32% year-on-year to CNY 3,739,251,867.46[5] - Non-current assets totaled CNY 1,802,034,941.35, compared to CNY 1,507,019,827.12, indicating a rise of about 19.6%[22] - Total current assets reached ¥1,937,216,926.11, an increase from ¥1,882,374,887.96 in the previous period[21] - Total liabilities amounted to CNY 1,935,821,435.40, an increase from CNY 1,858,823,901.11, reflecting a growth of about 4.1%[23] - Current liabilities decreased slightly to CNY 1,483,177,309.65 from CNY 1,503,881,432.98, a reduction of approximately 1.6%[22] - Shareholders' equity rose to CNY 1,803,430,432.06, up from CNY 1,530,570,813.97, marking an increase of approximately 17.8%[23] Cash Flow - Cash flow from operating activities showed a significant decline of 383.02%, resulting in a net cash outflow of CNY -43,519,728.40[5] - The company reported a net cash flow from operating activities of -¥43,519,728.40, a decrease of 383.02% compared to the previous year[15] - The net cash flow from operating activities was -¥141,881,125.61, compared to -¥40,652,629.81 in the same quarter last year, indicating a significant decline[40] - The total cash outflow from operating activities was ¥239,829,370.85, compared to ¥284,536,051.96 in the previous year, showing a reduction in cash outflow[40] - The company experienced a net increase in cash and cash equivalents of -¥86,561,400.01, compared to an increase of ¥55,603,907.64 in the same quarter last year[41] Investments and Shareholder Information - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 23.08% of the shares, with 132,441,168 shares pledged[9] - The company completed the acquisition of a 3.33% stake in the Heze Jingang Advanced Manufacturing Equity Investment Fund for ¥10 million[16] - Other equity investments increased to ¥781,642,554.19, accounting for 20.90% of total assets, up 53.36% from the previous period[11] - The total number of shareholders reached 45,174, indicating a stable shareholder base[9] Comprehensive Income - The total comprehensive income for Q1 2021 was ¥223,093,805.09, significantly higher than ¥34,810,144.04 in Q1 2020[31] - The company reported a significant increase in other comprehensive income, totaling ¥196,461,366.30 in Q1 2021[31] - The company’s other comprehensive income increased by 102.11% to ¥312,651,724.39, mainly due to fair value increases of financial assets held by subsidiaries[11] Operational Costs - Total operating costs for Q1 2021 were ¥378,040,728.36, up 4.9% from ¥360,308,646.98 in Q1 2020[30] - Research and development expenses for Q1 2021 were ¥14,409,179.35, slightly decreased from ¥14,700,980.86 in Q1 2020[30] - The company incurred financial expenses of ¥19,836,422.82 in Q1 2021, an increase from ¥18,890,738.43 in Q1 2020[30] Market Position and Strategy - The company plans to continue focusing on stable growth and product development despite recent financial challenges[5] - The company has not reported any new product launches or significant market expansions in this quarter[44]
太龙药业(600222) - 2021 Q1 - 季度财报